

DAFTAR PUSTAKA

1. Rothan HA and Byarareddy SN. The epidemiology and pathogenesis of coronavirus disease. *J autoimmun.* 2020. 1–4
2. Zhang N, Wang L, Deng X, Liang R, Su M, He C, *et al.* Recent advances in the detection of respiratory virus infection in humans. *J med vir.* 2020. 92(4): 408–17
3. Chen Y, Liu Q, and Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. *J med vir.* 2020. 92: 418–23
4. WHO. Coronavirus disease 2019 situation report. WHO. Geneva. 2022
5. Biswas M, Rahaman S, Biswas TK, Haque Z, and Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: A systematic review and meta-analysis. *Intervirol.* 2021. 64: 36–47
6. Kemenkes RI. Situasi terkini perkembangan novel coronavirus (COVID-19). Kemenkes RI. 2021
7. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19) revisi ke 5. Kemenkes RI. Jakarta. 2020
8. Burhan E, Susanto AD, Nasution SA, Ginajar E, Pitoyo CW, Susilo A, dkk. Pedoman tatalaksana COVID-19. Edisi 4. Tim gabungan PDPI, PERKI, PAPDI, PERDATIN dan IDAI. Jakarta. 2022
9. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, *et al.* Pathological finding of COVID-19 associated with acute respiratory distress syndrome. *Lancet.* 2020. 420–22
10. Das SK. The pathophysiology, diagnosis and treatment of coronavirus disease 2019 (COVID-19). *India j clin biochem.* 2020. 35 (4): 385–396.
11. Boechat JL, Chira I, Morais A and Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology-current perspectives. *Pulmonology.* 2021. 27(5): 423–37
12. Mizumoto K, Kagaya K, Zarebski A, and Chowell. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases

- on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance*. 2020. 1–5
13. Altschul DJ, Unda SR, Benton J, Ramos RDG, Cezayirli P, Mehler M, *et al*. A novel severity score to predict inpatient mortality in COVID-19 patient. *Nature*. 2020. 10: 1–8
 14. Terwangne C, Laouni J, Jouffe L, Lechien JR, Bouillon V, Place S, *et al*. Predictive accuracy of COVID-19 World Health Organization (WHO) severity classification and comparison with a Bayesian method-based severity score (EPI-SCORE). *Pathogens*. 2020. 9(880):1–14
 15. Knight SR, Ho A, Pius R, Buhan I, Carson G, Drake TM, *et al*. Risk stratification of patients admitted to hospital with COVID-19 using the ISARIC WHO clinical characterization protocol: development and validation of the 4C mortality score. *BMJ*. 2020. 370: 1–13
 16. Bonanad C, Blas SG, Santabalbina FT, Sanchis J, Gonzales VB, Facila L, *et al*. The effect of age on mortality in patients with COVID-19: A meta-analysis with 611,583 subjects. *JAMDA*. 2020. 21:915–918
 17. Martinez JJA, Mayo JC, Cifuentes MM, Soler PA, Martinez SG, Marin YR, *et al*. Generation and validation of in-hospital mortality prediction score in COVID-19 patient: Alba score. *Curr Med Res Opin*. 2021. 37(5):719–26
 18. Jehi L, Ji X, Millinovich A, Erzurum S, Merlino A, Gordon S, *et al*. Development and validation of a model for individualized prediction of hospitalization risk in 4536 patients with COVID-19. *PloS One*. 2020. 15(8): 1–15
 19. Fumagalli C, Ungar A, Rozzini R, Vannini, Coccia F, Cesaroni G, *et al*. Predicting mortality risk in older hospitalized persons with COVID-19: A comparison of the COVID-19 mortality risk score with frailty and disability. *JAMA*. 2021. 22: 1588–92.
 20. Gutierrez JM, Volkovs M, Poutanen T, Watson T and Rosella LC. Risk stratification for COVID-19 hospitalization: a multivariable model based on gradient-boosting decision trees. *CMAJ open*. 2021. 9(4): 1–9

21. Chen Z, Chen J, Zhou J, Lei F, Zhou F, Qin JJ, *et al.* A risk score based on baseline risk factors for predicting mortality in COVID-19 patients. *CMRO*. 2021. 37(6): 917–27
22. Bats ML, Rucheton B, Fleur T, Orleux A, Chemin C, Rubin S, *et al.* Covichem; A biochemical severity risk score of COVID-19 upon hospital admission. *PloS One*. 2021. 16(5): 1–15
23. Carbonell R, Urgeles S, Rodriguez A, Bosi M, Loeches Ig, Violan JS, *et al.* Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study. *Lancet*. 2021. 11: 1–9
24. Leoni MLG, Lombardelli L, Colombi D, Bignami EG, Pergolotti B, Rapetti F, *et al.* Prediction of 28 days mortality in critically ill patients with COVID-19: Development and internal validation of a clinical prediction model. *PloS One*. 2021. 16(7):1–13
25. Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan M, *et al.* Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care-An experience from South India. *Plos One*. 2022. 17(2): 1–16
26. Jones A, Pitre T, Junek M, Kapralik J, Patel R, Feng E, *et al.* External validation of the C mortality score among COVID-19 patients admitted to hospital in Ontario, Canada: a retrospective study. *Nature*. 2021. 11: 1–7
27. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, *et al.* Features of 20133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterization protocol: prospective observational cohort study. *BMJ*. 2020. 369: 1–12
28. Surendra H, Elyazar IR, Djaafara BA, Ekawati LI, Saraswati K, Adrian V, *et al.* Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospitalized-based retrospective cohort study. *Lancet*. 2021. 9: 1–9

29. Bertsimas D, Lukin G, Mingard L, Nohadini O, Orfanoudaki A, Stellato B, *et al.* COVID-19 mortality risk assessment: An international multicenter study. *PloS One*. 2020. 15(12): 1–13
30. Her AY, Bhak Y, Jun EJ, Yuan SL, Garg S, Lee S, *et al.* A clinical risk score to predict in-hospital mortality from COVID-19 in South Korea. *JKMS*. 2021. 36(15): 1–9
31. Chua F, Vanchesswaran R, Draper A, Vaghela T, Knight M, Mogal R, *et al.* Early prognostication of COVID-19 to guide hospitalization versus outpatient monitoring using a point-of-test risk prediction score. *BMJ*. 2021. 76: 696–703
32. Magro B, Zuccaro V, Novelli L, Zileri L, Celsa C, Raimondo F, *et al.* Predicting in hospital mortality from coronavirus disease 2019: A simple validated app for clinical use. *PloS One*. 2021. 16(1): 1–12
33. Marateb HR, Cub MV, Sami R, Javanmard SH, Mansourian M, Amra B, *et al.* Absolute mortality risk assessment of COVID-19 patient: the Khorsid COVID cohort (KCC) study. *BMC med res methodol*. 2021. 21(146):1–9
34. Bagnato G, Rosa DL, Lopollo C, Gaetano AD, Chiappalone M, Zirili N, *et al.* The COVID-19 assessment for survival at admission (CASA) index: 12 months observational study. *Front Med*. 2021. 8: 1–10
35. Lombardi Y, Azoyaa O, Szychowiak P, Belamine A, Lemaitre G, Boreaux M, *et al.* External validation of a prognostic score for COVID-19: a multicenter cohort study of patients hospitalized in Greater Paris University Hospitals. *Springer*. 2021. 47: 1426–39
36. Astuti I and Ysrafil. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and *host* response. *Diabetes and metabolic syndrome: clinical research and reviews*. Elsevier. 2020. 14: 407–12
37. Kumar S, Nyoda R, Maurya VK, and Saxena SK. Morphology, genome organization, replication and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In Saxena SK. *Medical virology from pathogenesis to disease control. Coronavirus disease 2019:*

- epidemiology, pathogenesis, diagnosis, and therapeutics. Springer. Singapore. 2020. 23–31
38. Srinivasan S, Cui H, Gao Z, Liu M, Lu S, Mkandawire W, *et al.* Structural genomic of SARS CoV-2 indicates evolutionary conserved functional regions of viral proteins. *Viruses*. 2020. 12(360): 1–17
 39. Yadav T and Axena SK. Transmission cycle of SARS-CoV and SARS-CoV-2. In Saxena SK. *Medical virology from pathogenesis to disease control. Coronavirus disease 2019: epidemiology, pathogenesis, diagnosis, and therapeutics.* Springer. Singapore. 2020. 33–42
 40. Bchetnia M, Gurrard C, Duchaine C and Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. *J Infect Public Health*. 2020. 1–10
 41. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokine including interleukin 6 in COVID-19-induced pneumonia and macrophage activation syndrome-like disease. *Autoimmune rev*. 2020. 19(6): 102763
 42. Weirsinga WJ, Rhodes A, Cheng AC, Peacock SJ, and Prescott HC. Pathophysiology, transmission, diagnosis, dan treatment of coronavirus disease 2019 (COVID-19). *JAMA*. 2020. 324 (8): 782–93
 43. Paz LO, Capodanno D, Montalescot G, and Angiolillo D. Coronavirus disease 2019-associated thrombosis and coagulopathy: a review of the pathophysiological characteristics and implications for antithrombotic management. *J Am Heart Assoc*. 2021. 10: 1–24.
 44. Bruin SD, Bos LD, Roon MA, Boer AMT, Schuurman AR, Simmeklinck MJAK, *et al.* Clinical features and prognostic factors in COVID-19: A retrospective cohort study. *E Bio Med*. 2021. 67: 1–9
 45. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehwarat TS, *et al.* Extrapulmonary manifestation COVID-19. *Nat Med*. 2020. 1–17
 46. Mason J. Pathogenesis of COVID-19 from a cell biologic perspective. *Eur Respir J*. 2020. 1–7
 47. Cevik M, Kuppalli K, Kindrachuk, and Peiris M. Virology, transmission, and pathogenesis SARS-CoV-2. *BMJ*. 2020. 371: 1–6.

48. Das SK. The pathophysiology, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). *India J Clin Biochem.* 35 (4): 385–96.
49. Azer SA. COVID-19: pathophysiology, diagnosis, complication, and investigational therapeutics. *NMNI.* 2020. 37: 1–8
50. Huang C, Li X, Ren L, Zhao J, Hu Y, Zhang L, *et al.* Clinical feature of patient infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020. 1–10
51. Xu, P, Zhou Q, and Xu J. Mechanism of thrombocytopenia in COVID-19 patient. *Ann Hematol.* 2020. 1–4
52. Castelli R and Gidaro A. Abnormal hemostatic parameter and risk of thromboembolism among patients with COVID-19 infection. *Hematol.* 2020. 9(1-2): 1–4
53. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, *et al.* Epidemiological and clinical characteristic of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020. 395: 507–13
54. Ng JH, Bijol V, Sparks MA, Sise ME, Izzedine H, and Jhaveri KD. Pathophysiology and pathology of acute kidney injury in a patient with COVID-19. *Advanced chronic kidney disease.* 2020. 27(5): 365–76
55. Paek JH, Kim Y, Park WY, Jin K, Hyun M, Lee JY, *et al.* Severe acute kidney injury in COVID-19 patients is associated with in-hospital mortality. *PloS One.* 2020. 1–12
56. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, *et al.* COVID-19: immunopathogenesis and immunotherapeutics. *Nature.* 2020. 5(128): 1–8
57. Toor SM, Saleh R, Nair VS, Taha RW and Elkord E. T-cell responses and therapies against SARS-CoV-2 infection. *The journal of cells, molecules, systems, and technologies.* 2020. 162: 30–43
58. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, *et al.* Pathological finding of COVID-19 associated with acute respiratory distress syndrome. *Lancet.* 2020. 420–22

59. Rosiyanti L dan Hadi I. Respon imunitas dan badai sitokin Severe Acute Respiratory Synndrome Corona Virus 2. JKMM. 2020. 11(02): 176–201
60. Wan S, Yi Q, Fan S, Lv J, Zhang X, Gou L, *et al.* Characteristic of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020
61. Song M, Graubard BI, Rabkin CS and Engels EA. Neutrophil to lymphocyte ratio and mortality in the United States general population. Nature. 2021. 11(464): 1–7
62. Qun S, Wang Y, Chen J, Huang X, Guo H, Lu Z, *et al.* Neutrophil to lymphocyte ratios are closely associated with the severity and course of non-mild COVID-19. Front Immunol. 2020. 11(2160). 1–11
63. Li X, Liu C, Mao Z, Xiao M, Li W, Qi W, *et al.* Predictive values of neutrophil to lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and metanalysis. BMC. 2021. 24(646): 1–10
64. Erdogan A, Can FE, and Gonullu H. Evaluation of the prognostic role of NLR, LMR, PLR, and LCR ratio in COVID-19 patients. J Med Virol. 2021. 1–5
65. Fuad A, Oehadian A, Prihatni D, and Marthoenis. Neutrophil to lymphocyte ratio and COVID-19 symptom-based severity at admission. Althea Med J. 2021. 8(1): 1–6
66. Azkur AK, Akdis M, Azkur D, Sokolowka M, De ven WV, Bruggen MC, *et al.* Immune response to SAR-CoV-2 and mechanisms of immunopathological change in COVID-19. Allergy. 2020. 75: 1564–81
67. Fara A, Mitrev Z, Rosalia RA, and Assas BM. Cytokine *storm* and COVID-19: a chronicle of proinflammatory cytokines. Open Biol. 2020. 1–12
68. Sun X, Wang T, Dayong C, Hu Z, Chen J, Liao H, *et al.* Cytokine *storm* intervention in the early stages of COVID-19 pneumonia. Cytokine and growth factor reviews. 2020. 53: 38–42
69. Anka AU, Tahir MI, Abubakar SD, Alsabbagh M, Zian Z, Hamedifar H, *et al.* Coronavirus disease 2019 (COVID-19): An overview of the

- immunopathology, serological diagnosis and management. *Scand J Immunol.* 2021. 93:1–12
70. Kermani EK, Khalili H, and Karimzadeh I. Pathogenesis, clinical manifestation and complication of COVID-19. *Future Microbiol.* 2020. 15 (13): 1287–1305
 71. WHO. Diagnostic test for SARS-CoV-2. Interim guidance. 2020. Geneva. WHO
 72. Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation, and treatment. *BMJ.* 2020. 0: 1–9
 73. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, *et al.* A rapid advice Guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). *Mil Med Res.* 2020. 7(4): 1–23
 74. Pascarella G, Strimia A, Piliago C, Bruno F, Del Buono R, Costa F, *et al.* COVID-19 diagnosis and management: a comprehensive review. *J Intern Med.* 2020. 1–15
 75. Shahbazi F, Solgi M, and Khazaei S. Predisposing risk factors for COVID-19 infection: a case-control study. *Caspian J Intern Med.* 2020. 11(1): 495–500.
 76. Xia Y, Jin R, Zhao J, Li W, and Sehn H. Risk of COVID-19 for a patient with cancer. *Lancet.* 2020. 21:180
 77. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, *et al.* Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J.* 2020. 55: 1–14
 78. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, *et al.* Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. *Cancer Discov.* 2020. 10: 789–91
 79. Alshamrani MM, AL-Saed A, Al-Zunitan M, Almulhem R, and Almohrij S. Risk of COVID-19 morbidity and mortality among healthcare workers working in large tertiary care hospital. *Int J Infec Dis.* 2021. 109: 238–43

80. Yustinawati R and Achadi A. Risk factors for mortality in patients with COVID-19: a systematic review. Proceeding the 7th International conference on public health. 2020. 1–11
81. Adimara A, Prahasanti K, dan Airlangga MP. Obesitas mempengaruhi tingkat keparahan pasien COVID-19. JIKW. 2021. 10(2): 222–42
82. Wolff D, Nee S, Hickey NS and Marschollek M. Risk factor for COVID-19 severity and fatality: a structured literature review. J Infect. 2021. 49: 15–28
83. Alkautsar A. Hubungan penyakit komorbid dengan tingkat keparahan pasien COVID-19. JMH. 2021. 1488–95
84. Faustine I, malik A, Andrajati R, and Wanandi SI. Clinical characteristics and severity profile of COVID-19 patient with hypertension in Palu, Central Sulawesi. Indonesian J Pharm. 2021. 32(40): 563–72
85. Mubarik S, Liu X, Eshak ES, Liu K, Liu Q, Wang F, *et al.* The association of hypertension with the severity of and mortality from COVID-19 in the early stage of an epidemic in Wuhan, China: A multicenter retrospective cohort study. Frontier. 2021. 8: 1–13
86. Kostadinova T, Todorova T, Stoykova Z, Niyazi D, Bozhkova M, Bizheva S, *et al.* Dynamic of COVID-19 and demographic characteristics as predisposing risk factors for SARS-CoV-2 infection: a hospital-based, one center retrospective study. Biotechnol Biotechnol Equip. 2022. 35(1): 1869–73
87. Wang D, Hu B, Hu C, Zhu F, liu X, Zhang K, *et al.* Clinical characteristic of 138 hospitalized patient with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc. 2020. 323: 1061–69
88. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, *et al.* Risk factor for severity and mortality in adult COVID-19 in patients in Wuhan. J Allergy Clin Immunol. 2020. 146(1): 110–19
89. Mudatsir M, Fajar JK, Wulandari L, Soegiarta G, Ilmawan M, Purnamasari Y, *et al.* Predictor of COVID-19 severity: a systematic review and metanalysis. F1000research. 2020. 9(1107): 1–26

90. Sitorus JS, Antara NY, Elviani R, Ahmad Z, Hudari H, and Sangalang RV. The risk factor for mortality in COVID-19 patients in Mohammad Hoesin Hospital, Palembang, Indonesia. *JIKM*. 2021. 12(1):69–76
91. Vahey GM, McDonald E, Marshall K, Martin SW, Chun H, Herlihy R, *et al.* Risk factors for hospitalization among persons with COVID-19-Colorado. *PloS One*. 2021. 16(9): 1–17
92. Wang Z, Deng H, Ou C, Liang J, Wang Y, Jiang M, *et al.* Clinical symptoms, comorbidities and complications in severe and non-severe patients with COVID-19. *Medicine*. 2020. 99(48): 1–8
93. Alali AS, Alshehri AO, Assiri A, Khan S, Alkathiri MA, Almohammed OA, *et al.* Demographics, comorbidities and outcomes among young and middle-aged COVID-19 patients in Saudi Arabia. *Saudi Pharm J*. 2021. 29: 833–42
94. Chen J, Liu Y, Qin J, Ruan C, Zeng X, Xu A, *et al.* hypertension as an independent risk factor for severity and mortality in patient with COVID-19: a retrospective study. *BMJ*. 2021. 0: 1–8
95. Muhammad ID. Mekanisme potensial peningkatan derajat keparahan infeksi COVID-19 diabetes melitus. *Wellness and healthy magazine*. 2021. 3(1): 29–36
96. Zheng Z, Ye S, Xu B, Zhao J, Liu H, and Peng J. Risk factors of critical and mortality COVID-19 cases: A systematic literature review and meta-analysis. *J Infect*. 2020. 81: 16–25
97. Gibertoni D, Reno C, Rucci P, Fantini MP, Buscaroli A, Mosconi G, *et al.* COVID-19 incidence and mortality in non-dialysis chronic kidney disease patient. *PloS One*. 2021. 16(7): 1–11
98. Gerayeli FV, Milne S, Cheung C, Li X, Yang CWT, Tam A, *et al.* COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. *E Clin Med*. 2021. 33: 1–14
99. Hasehemi N, Viveiros K, Redd WD, Zhou JC, McCarty TR, Bazarbashi AN, *et al.* Impact of chronic liver disease on outcomes of hospitalized patient with COVID-19: A multicenter United States experience. *Liver Int*. 2020. 00: 1–7

100. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, *et al.* Cancer patient in SARS-CoV-2 infection: A nationwide analysis in China. *Lancet Oncol.* 2020. 21 (3): 335–37
101. Mehta V, Gole S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, *et al.* Case fatality rate of cancer patients with COVID-19 in New York hospital system. *Cancer Discov.* 2020. 10:935–41
102. Garcia JB, Verdegel RO, Pallardo FV, Ferreres J, Rodriguez M, Mulet S, *et al.* Sepsis and coronavirus disease 2019: common features and anti-inflammatory therapeutic approaches. *Crit Care Med.* 2020. 1–4
103. Drake TM, Riad AM, Fairfield CJ, Egan C, Knight SR, Pius R, *et al.* Characteristic of in-hospital complication associated with COVID-19 using the ISARIC WHO clinical characterization protocol UK: A prospective, multicentre cohort study. *Lancet.* 2021. 398: 223–38.
104. Azer SA. COVID-19: pathophysiology, diagnosis, complication and investigation therapeutics. *NMNI.* 2020. 37: 1–8
105. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Hemost.* 2020. 18:1421–24.
106. Klok FA, Kruip MJHA, van der Meer NJM, *et al.* Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res.* 2020. 191:145–47
107. Zhang L, Yan X, Fan Q, *et al.* D-dimer levels on admission to predict in-hospital mortality in patients with COVID-19. *J Thromb Hemost.* 2020. 18:1324–29
108. Ozdemir O. Coronavirus disease 2019 (COVID-19): Diagnosis and management. *Ercyes Med J.* 2020. 42(3): 242–47
109. Hasabo EA, Ayyad FA, Eldeen SA, Noureldaim MK, Abdallah TA, Ahmed YT, *et al.* Clinical manifestations, complications, and outcomes of patients with COVID-19 in Sudan: a multicenter observational study. *Trop Med Int Health.* 2021. 49(91): 1–13
110. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus

- pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020. 395: 507–13
111. Jin M, Lu Z, Zhang X, Wang Y, Wang J, Cai Y, *et al*. Clinical characteristics and risk factors of fatal patients with COVID-19: a retrospective cohort study in Wuhan, China. *BMC Infect Dis*. 2021. 21(951): 1–13.
 112. Silva Ramos FJS, Freitas FGR, and Machado FR. Sepsis in patients hospitalized with coronavirus disease 2019: how often and how severe? *Wolther kluwer health*. 2021. 27(5): 474–80.
 113. Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, Fleischmann-Struzek C, Pletz MW, Netea MG, *et al*. COVID-19 as a cause of viral sepsis: a systematic review and meta-analysis. *Medrxiv*. 2020. 1–40.
 114. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, *et al*. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. *JAMA Intern Med*. 2020. 180(11): 1436–47.
 115. Ketcham SW, Bolig TC, Molling DJ, Flander SA, and Prescott HC. Causes and circumstances of death among patients hospitalized with COVID-19: a retrospective cohort study. *Ann Am Thorac Soc*. 2021. 18(6): 1076–79
 116. Mochtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi and Hassanzadeh G. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. 2020. *J Mol Histol*. 51: 613–28
 117. Cui J, Yuan B, Li Y, Li Z, and Yuan Y. The clinical characters and prognosis of COVID19 patients with multiple organ dysfunction. *Medicine*. 2021. 110(41): 1–11
 118. Parimoo A, Biswas A, Baitha U, Gupta G, Pandey S, Ranjan P, *et al*. Dynamic of inflammatory markers in predicting mortality in COVID-19. *Cureus*. 2021. 13(10): 2–8
 119. Betti M, Bertolotti M, Ferrante D, Roveta A, Pelazza C, Giaccherio F, *et al*. Baseline clinical characteristics and prognostic factors in hospitalized COVID-19 patients aged ≤ 65 years: A retrospective observational study. *PloS One*. 2021. 16(3): 1–10.

120. Izcovich A, Ragusa MA, Tortosa F, Lavena MA, Agnoletti C, Bengolea A, *et al.* Prognostic factors for severity and mortality in a patient infected with COVID-19: a systematic review. *PloS One*. 2020. 15(11): 1–30
121. Yanez ND, Weiss NS, Romand JA, and Treggiarri MM. COVID-19 mortality risk for older men and women. *BMC Public Health*. 2020. 20(1724): 1–7
122. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, *et al.* Predictor of mortality for a patient with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur Respir J*. 2020. 55: 1–8.
123. Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, *et al.* Characteristic and prognostic factors of disease severity in patients with COVID-19: the Beijing experience. *J. Autoimmun*. 2020. 112: 1–7
124. Prasetya IB, Cucunawangsih, Lorens JO, Sungono V, El-Khobar KE and Wijaya RS. Prognostic value of inflammatory markers in a patient with COVID-19 in Indonesia. *Clin Epidemiol Glob Health*. 2021. 11: 1–6
125. Dahlan SD. Penelitian prognostik dan sistem skoring: disertai praktik dengan SPSS dan STATA. Alqaprint. Jakarta. 2011
126. Vogenberg FR. Predictive and prognostic model: Implications for healthcare decision-making in modern recession. *Am health drug benefits*. 2009. 2(6): 218–223
127. Suarthana E. Model diagnostik dan prognostik di bidang kesehatan kerja. *Majalah kedokteran FK UKI*. 2012. 28(2): 85–93
128. Smeden MV, Reitsma JB, Riley RD, Collins GS, and Moons KG. Clinical prediction models: diagnosis versus prognosis. *J clin epi*. 2021, 132: 142–45
129. Yanez ND, Weiss NS, Romand JA, And Treggiari. COVID-19 mortality risk for older men and women. *BMC Public Health*. 2020. 20: 1–7
130. Raimondi F, Novelli L, Ghirardi A, Russo FM, Pellegrini D, Biza R, *et al.* COVID-19 and gender: lower rate but same mortality of severe disease in woman-an observational study. *BMC*. 2021. 21(96): 1–11

131. Xiong W, Lu L, Zhang B, Luo J, Li W, He L, *et al.* Association of consciousness impairment and mortality in people with COVID-19. *Acta Neurol Scand.* 2021. 144: 251–59
132. Chatterjee NA, Jensen PN, Harris AW, Nguyen DD, Huang HD, Cheng RK, *et al.* Admission respiratory status predicts mortality in COVID-19. *Influenza Other Respir Viruses.* 2021. 15: 569–72
133. Tam EMY, Kwan YK, Ng YY and Yam PW. Clinical course and mortality in older patients with COVID-19: a cluster-based study in Hong Kong. *Hong Kong Med J.* 2022. 28: 215–22
134. Yildiz H, Zapatero DC, Pierman G, Pothan L, De Greef J, Nana FA, *et al.* Validation of neutrophil to lymphocyte ratio *cut-off* value associated with high in hospital mortality in COVID-19 patients. *Int J Gen Med.* 2021. 14: 5111–17
135. Suruthy A, Vishwanathan NG, and Bijjaragi S. Significance of D-dimer in assessment of severity and mortality of COVID-19 patients a tertiary care hospital study. 2022. 8(1): 70–76
136. Violi F, Cangemi R, Romiti GF, Ceccarelli G, Oliva A, Alessandri F, *et al.* Is albumin predictor of mortality in COVID-19. *Antioxid Redox Signal.* 2021. 35(2): 1–13
137. Salik F, Uzundere O, Bicak M, Akelma H, Akgundu M, Korhan Z, *et al.* Liver function as a predictor of mortality COVID-19: A retrospective study. *Ann Hepatol.* 2021. 26: 1–6
138. Jewell PD, Bramham K, Galloway J, Post F, Norton S, Teo J, *et al.* COVID-19 related acute kidney injury: incidence, risk factors and outcomes in a large UK cohort. *BMC Nephrol.* 2021. 22: 1–11
139. Carrasco-Sanchez FJ, Lopez-Carmona D, Matinez-Marcos JF, Perez-Belmonte LM, Hidalgo-Jimenez A, Buonaiuto V, *et al.* Admission hyperglycemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetic status: data from the Spanish SEMI-COVID-19 registry. *Ann Med.* 2021. 53(1): 103–16

140. Ahmed S, Ahmed ZA, Siddiqui I, Rashid NH, Mansoor M and Jafri L. Evaluation of serum ferritin for prediction of severity and mortality in COVID-19- A cross-sectional study. *Ann Med Surg.* 2021. 63: 1–5
141. Zhou J, He W, Liang J, Wang L, Yu W, bao W, *et al.* Association of interleukin-6 levels with morbidity and mortality in patients with coronavirus disease 2019 (COVID-19). *Jpn J Infect Dis.* 2021. 71: 239–98
142. Twe CW, Khoo DKY, Law KB, Nordin NSA, Sathasivan S, Lim KC, *et al.* The role of procalcitonin in predicting risk of mechanical ventilation and mortality among moderate to severe COVID-19 patients. *BMC infectious disease.* 2022. 22(378): 1–13
143. Haryati, Isa M, Assagaf A, Nurrasyidah I, Kusumawardhani E, Suhartono E, *et al.* Clinical and labotaory features of COVID-19 in Ulin referral hospital of South Kalimantan: predictor of clinical outcome. *J Trop Life Sci.* 2021. 11(3): 299–307
144. Kheyri Z, Metanat S, Hosamirudsari H, Akbarpour S, ShojaeiM, Faraji N, *et al.* Neutrophil-to-lymphocyte ratio *cut-off* point for COVID-19 mortality: A retrospective study. *Acta med Iran.* 2022. 60(1): 32–9
145. Nugroho J, Wardhana A, Maghfirah I, Mulia EPB, Rachmi DA, Ayun MQ, *et al.* Relationship of D-dimer with the severity and mortality in SAR-COV-2 patient: A meta-analysis. *Int J Lab Hematol.* 2020. 00: 1–6
146. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, *et al.* D-dimer as a biomarker for disease severity and mortality in COVID-19 patient: a case-control study. *J Intensive Care.* 2020. 8(49): 1–11
147. Zerbato V, Sanson G, De Luca M, Bella SD, Masi A, Caironi P, *et al.* The impact of serum albumin levels on COVID-129 mortality. *Infect Dis Rep.* 2020. 14: 278–86
148. Heber S, Pereyra D, Schrottmaier WC, Kammerer K, Santol J, Rumpf B, *et al.* A model predicting mortality of hospitalized COVID-19 patients four days after admission: Development, Internal and temporal-external validation. *Front Cell Infect Microbiol.* 2022. 11: 1–10

149. Carrasco-Sanchez FJ, Lopez-Carmona D, Matinez-Marcos JF, Perez-Belmonte LM, Hidalgo-Jimenez A, Buonaiuto V, *et al.* Admission hyperglycemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetic status: data from the Spanish SEMI-COVID-19 registry. *Ann Med.* 2021. 53(1): 103–16
150. Ahmed S, Ahmed ZA, Siddiqui I, Rashid NH, Mansoor M and Jafri L. Evaluation of serum ferritin for prediction of severity and mortality in COVID-19- A cross-sectional study. *Ann Med Surg.* 2021. 63: 1–5
151. Zhou J, He W, Liang J, Wang L, Yu W, bao W, *et al.* Association of interleukin-6 levels with morbidity and mortality in patients with coronavirus disease 2019 (COVID-19). *Jpn J Infect Dis.* 2021. 71: 239–98
152. Twe CW, Khoo DKY, Law KB, Nordin NSA, Sathasivan S, Lim KC, *et al.* The role of procalcitonin in predicting risk of mechanical ventilation and mortality among moderate to severe COVID-19 patients. *BMC infectious disease.* 2022. 22(378): 1–13
153. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R and Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. *Biol. Sex Differ.* 2020. 11(29): 1–13.
154. Pandit RA, BN Gagana, Vaity C, Mulakavalupil B, Choudhary JS, Jain V, *et al.* Clinical characteristics and outcomes of COVID-19 patient hospitalized in intensive care unit. *Indian J. Crit. Care Med.* 2021. 25 (9): 992–1000
155. Soto A, Laveriano DMQ, Azanero J, Chumpitaz R, Claros J, Salazar L, *et al.* Mortality and associated risk factors in patients hospitalized due to COVID-19 in a Peruvian reference hospital. *Plos One.* 2022. 17(3): 1–15
156. Pya Y, Bekbosssynova M, Gaipor A, Lesbekov T, Kapyshev T, Kuanyshbek A, *et al.* Mortality predictor of hospitalized patients with COVID-19: A retrospective cohort study from Nur-Sultan, Kazakstan. *Plos One.* 16(12): 1–15
157. Martinez AO, Fragoso JLC, Jimenez JV, Lozano-Cruz OA, Ortiz-Brizuela E, Tovar-Mendez VH, *et al.* In-hospital mortality from severe

- COVID-19 in tertiary care center in Mexico City; causes of death, risk factor and the impact of hospital saturation. *Plos One*. 16(2): 1–17
158. Bhaskaran K, Bacon S, Evan SJ, Bates CJ, Rentsch CT, MacKenna B, *et al*. Factors associated with deaths due to COVID-19 versus other causes: population-based cohort Analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. *Lancet*. 2021. 6: 1–13
159. Chatterjee B, Karandikar RL and Mande SC. The mortality due to COVID-19 in different nations is associated with the demographic character of the nation and the prevalence of autoimmunity. *Curr Sci*. 2021. 120 (3): 501–8
160. Osaki Y, Otsuki H, Imamoto A, Kinjo A, Fujii M, Kuwabara Y, *et al*. Why are COVID-19 mortality rates by country or region so different? An ecologic study of factors associated with mortality from Novel Coronavirus infections by country. *Yonago Acta Med*. 2021. 64(1): 80–91
161. CDC. COVID-19 data review: Update on COVID-19 related mortality . CDC. US. 2022
162. Nguyen Nt, Chinn J, Ferrante MD, Kirby KA, Hohmann SF, and Amin A. Male gender is a predictor of higher mortality in hospitalized adults with COVID-19. *Plos One*. 2021. 16(7): 1–6
163. Al-Jarallah M, Rajan R, Dashti R, Al-Saber A, Brady PA, Abdelnaby H, *et al*. In-hospital mortality in SAR_CoV-2 stratified by sex differences: A retrospective cross-sectional cohort study. *Ann Med Surg*. 2022. 79: 1–9
164. Chaturverdi R, Lui B, Aaronson JA, White RS and Samuel JD. COVID-19 complications in males and females: recent development. *J Comp Eff Res*. 2022. 11(9): 689–98
165. Griffith DM, Sharma G, Holliday CS, Enyia OK, Valliere M, Semlow AR, *et al*. Men and COVID-19: A biopsychosocial approach to Understanding Sex Differences in Mortality and recommendations for practice and policy interventions. *Prev. Chronic Dis*. 2020. 17: 1–10

166. Damayanthi HDWT and Weerasekara I. Factor associated for mortality of older people with COVID-19: A systematic review and meta-analysis. *Gerontol Geriatr Med.* 2021. 7: 1–12
167. Naaraayan A, Nimkar A, Hasan A, Pant S, Durdevic M, Elenius H, *et al.* Analysis of male sex as a risk factor in older adults with Coronavirus disease 2019: A retrospective cohort study from the New York City Metropolitan region. *Cureus.* 2020. 12(8): 991
168. Haryati, Isa M, Assagaf A, Nurrasyidah I, Kusumawardhani E, Suhartono E, *et al.* Clinical and laboratory features of COVID-19 in Ulin referral hospital of South Kalimantan: Predictors of clinical outcome. *J Trop Life Sci.* 2021. 11 (3): 299–307
169. Dadras O, AsyedAlinaghi AS, Karimi A, Shamsabadi A, Qaderi K, Ramezani M, *et al.* COVID-19 mortality and its predictor in the elderly: A systematic review. *Health Sci Rep.* 2022. 5: 1–15
170. Tarteret P, Strazzulla A, Rouyer M, Gore C, Bardin G, Noel C, *et al.* Clinical features and medical care factors associated with mortality in French nursing homes during the COVID-19 outbreak. *Int J Infect Dis.* 2021. 104: 125–31
171. Ikram AS and Pillay S. admission vital sign as predictors of COVID-19 mortality: a retrospective cross-sectional study. *BMC.* 2022. 22(68): 1–10
172. Mueller AL, McNamara MS, and Sinclair DA. Why does COVID-19 disproportionately affect older people? *Aging.* 2020. 12(10): 9959–82
173. Esmaeili ED, Fakhari A, Naghili B, Khodamoradi F, and Azizi H. Case fatality and mortality rate, sociodemographic profile, and clinical features of COVID-19 in the elderly population: A population-based registry study in Iran. *J Med Virol.* 2022. 94: 2126–32
174. Loganathan S, Kuppusamy M, Wankhar W, Gurugubelli KR, Mahdevappa VH, Lepcha L, *et al.* Angiotensin-converting enzyme 2 (ACE2): COVID-19 gateway to multiple organ failure. *Respi Physiol Neurobiol.* 2021. 281: 1–14

175. Baj J, Juchnowicz HK, Teresinski G, Buszewicz G, Ciesielka M, Sitarz E, *et al.* COVID-19: specific and non-specific clinical manifestation and symptoms: The current state of knowledge. *J Clin Med.* 2020. 9(1753): 1–22
176. Eskandar EN, Atschul DJ, Ramos RG, Cezayirli P, Unda SR, Benton J, *et al.* Neurologic syndromes predict higher in-hospital mortality in COVID-19. *Neurology.* 96(11): 1527–51
177. Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, and Hassanzadeh G. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. *J Mol Histol.* 2020. 51: 613–28
178. Xiong W, Lu L, Zhang B, Luo J, Li W, He L, *et al.* Association of consciousness impairment and mortality in people with COVID-19. *Acta Neurol Scand.* 2021. 14: 251–59
179. Alizadehsani R, Eskandarian R, Behjati M, Zahmatkesh M, Roshanzamir M, Izadi NH, *et al.* Factor associated with mortality in hospitalized cardiovascular disease patients infected with COVID-19. *Immun Inflamm Dis.* 2022. 10: 1–10
180. Jee Y, Kim YJ, Oh J, Kim YJ Ha EH and Jo I. A COVID-19 mortality prediction model for Kore patients using nationwide Korea disease control and prevention agency database. *Sci Rep.* 2022. 12: 1–7
181. Liu L, Ni SY, Yan W, Lu QD, Zhao YM, Xu YY, *et al.* Mental and neurological disorder and risk of COVID19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action. *E Clin Med.* 2021. 40: 1–40
182. Kurniawan H, Rumende CM, Setiati S, Kumalawati J, and Deslanthy BT. Diagnostic model of COVID-19 infection based on the combination of clinical symptoms, chest radiography, and laboratory test. *Indones J Intern Med.* 2022. 54(3): 419–27
183. Gromov MS, Rogacheva SM, Barulina MA, Reshetnikov AA, Prokhozhev DA, and Fomin AY. Analysis of some physiological and biochemical indices in patients with COVID-19 pneumonia using mathematical methods. *J Evol Biochem Physiol.* 2021. 57(6): 1394–07

184. Ahmad S, Kumar P, Shekhar S, Saha R, Ranjan A and Pandey S. Epidemiological, clinical, and laboratory predictor of in-hospital mortality among COVID-19 patients admitted in a tertiary COVID-19 dedicated hospital, Northern India: A retrospective observational study. *J Prim Care Community Health*. 12: 1–9
185. Biarwa M, Kumar R, Ajmal M, Bahurupi Y and Kant R. predictor of critical illness and mortality based on symptoms and initial physical examination for the patient with SARS-CoV-2: A retrospective cohort study. *J Infect Public Health*. 2021. 14: 1028–34
186. Rechtman E, Curtin OP, Navarro E, Nienberg S and Horton MK. Vital sign assessed in initial clinical encounters predicts COVID-19 mortality in an NYC hospital system. *Sci Rep*. 2020. 10: 1–6
187. Wang JM, Liu W, Chen X, McRae MP, McDevitt, and Fenyo D. Predictive modeling of morbidity and mortality in patients hospitalized with COVID-19 and its clinical implication: algorithm development and interpretation. *J Med Internet Res*. 2021. 23(7): 1–16
188. Mason J. Pathogenesis of COVID-19 from a cell biologic perspective. *Eur Clin Respir J*. 2020. 1–7
189. Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation, and treatment. *BMJ*. 2020. 0: 1–9
190. Zhao Z, Chen A, Hou W, Hou W, Graham JM, Li H, *et al*. Prediction model and risk score of ICU admission and mortality in COVID-19. *Plos One*. 2020. 15(7): 1–14
191. Lavezzo E, Franchin E, Ciavarella C, Dannenburg GC, Barzon L, Vecchio CD, *et al*. Suppression of COVID-19 in the municipality of Vo, Italia. *Nature*. 2020. 1–23
192. Meija F, Medina C, Cornejo E, Morello E, Vasquez S, Alave J, *et al*. Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru. *Plos One*. 2021. 15(12): 1–12
193. Abbas AK, Lichtman AH, and Pillai S. Cellular and molecular immunology. 8th edition. Elsevier. 2021. 16 – 20

194. Delves PJ, Martin SJ, Buton DR, and Roitt IM. Innate immunity. In Roitt's essential immunology. 13th edition. 2017. Willey Blackwell. UK. 4–45
195. Varim C, Yaylaci S, Demirci T, Kaya T, Nalbant A, Dheir H, *et al.* Neutrophil count to albumin ratio as a new predictor of mortality in patients with COVID-19 infection. 2020. Rev Assoc Med Bras. 66(2): 77–81
196. Yang AP, Liu JP, Tao WQ, and Li HM. The diagnostic dan predictive role of NLR, d-NLR dan PLR pada COVID-19 patient. Journal of international immunopharmacology. 2020. 84: 1–8
197. Sarkar S, Khanna P, and Singh AK. The impact of neutrophil-lymphocyte count ratio in COVID-19: A systematic review and meta-analysis. 2022. J Intensive Care Med. 2022. 3(7): 875–69
198. Tufa A, Gebremariam TH, Manyazewal T, Asrat Y, Genitet T, Hundie TG, *et al.* Limited value of neutrophil-to-lymphocyte ratio and serum creatinine as point-of-care biomarkers of disease severity and infection mortality in patients hospitalized with COVID-19. Plos One. 17(10): 1–14
199. Hassan S, Ferrari B, Rossio R, La Mura V, Artoni A, Gualtierotti R, *et al.* The usefulness of D-dimer as a predictive marker for mortality in patients with COVID-19 hospitalized during the first wave in Italy. Plos One 2022. 17(7): 1–7
200. Suastika NKW and Suega K. The optimal cutoff value of D-dimer level to predict in-hospital mortality in severe cases of coronavirus disease 2019. Maced J Med Sci. 2021. 18(9): 1561–64
201. Li Y, Deng Y, Ye L, Sun H, Du S, Huang H, *et al.* Clinical significance of plasma D-dimer in COVID-19 mortality. Front Med. 2021. 8: 1–13
202. Soni M, Gopalakrishnan R, Vaishya R, and Pranu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 438 cases. Diabetes Metab Syndr: Clin Res Rev. 2020. 14: 2245–49
203. Poudel A, Poudel Y, Adhikari A, Aryail BB, Debika D, Bajracharya T, *et al.* D-dimer as a biomarker for assessment of COVID-19 prognosis:

- D-dimer levels on admission and its role in predicting disease outcomes in hospitalized patients COVID-19. *Plos One*. 2021. 16(8): 1–13
204. Milenkovic M, Hadzibegovic A, Kovac M, Jovanovic B, Stanisavljevic J, Djikic M, *et al.* D-dimer, CRP, PCT, and IL_6 levels at admission o ICU can predict inhospital mortality in patients with COVID-19 pneumonia. *Ox Med Cell Longev*. 2022. 1–9
205. Ahmed K, Ebru C, Emre E, Aykut O, Yasemin K, Beyza S, *et al.* Early creatinine and e-GFR change as prognostic predictor of COVID-19 patients. *Turk J Biochem*. 2022. 47(3): 237–45
206. Jewell PD, Bramham K, Galloway J, Post F, Norton S, Teo J, *et al.* COVID-19 related acute kidney injury: incidence, risk factor, and outcomes in a large UK cohort. *BMC Nephrol*. 2021. 22(359): 1–11
207. La Porta E, Baiardi P, Fassina L, Faragli A, Perna S, Tovagliari F, *et al.* The role of kidney dysfunction in COVID-19 and the influence of age. *Sci Rep*. 2020. 12: 1–9
208. Zhang WY, Xu Cg, Wang CG, Liu YY, Huang JA, Jiang JH, *et al.* Prognostic value of serum creatinine in severe COVID-19 patient in Wuhan, China: A restrospective cohort study. *Res Q*. 1–13
209. Habib HM, Ibrahim S, Zaim A, and Ibrahim WH. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators. *Biomed Pharmacother*. 2021. 136: 1–10
210. Chen J, He ZX, and Wang FK. Evaluation of ferritin level in COVID-19 patients and its inflammatory response. *Appl Nano Sci*. 2022. 1–7
211. Alroomi M, Rajan R, Omar AA, Alsaber A, Pan J, Fatemi M, *et al.* Ferritin level: A predictor of severity and mortality in hospitalized COVID-19 patients. *Immun Inflamm Dis*. 2021. 9: 1648–55
212. Quirit AM, Sorreda J, Pinera R and Tobias KK. Serum ferritin level as a prognostic marker of 30 days in hospital mortality of coronavirus disease 2019 (COVID-19) pneumonia at world city medical center: A retrospective, observational cohort, single-center study. *Open Access J*. 3(3): 20–30

213. Mourji D, Abouelfath Z, Abassor T, Biaz A, Elmachtani S, Doghmi N, *et al.* Association between ferritin and COVID-19 mortality in 1310 Moroccan patients. *Cross Current Int J Med Biosci.* 2022. 5–55
214. Deng F, Zhang L, Lyu L, Lu Z, Gao D, Ma X, Guo Y, *et al.* Increased levels of ferritin on admission predict intensive care unit mortality in patients with COVID-19. *Med Clin.* 2021. 156(7): 324–31
215. Herold T, Jurinovic V, Anreich C, Lipworth BJ, Hellmuth JC, Von Bergwelt-Baildon M, *et al.* Elevated level of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J Allergy Clin Immunol.* 2020. 146: 128–36
216. Ghanzafari T, Ghaffarpour S, Arabkheradmand J, and Salehi M. Interleukin-6 as a potential predictor of COVID-19 disease severity in hospitalized patient and its association with clinical laboratory routine tests. *Imun Reg.* 2020. 3(1): 29–37
217. Liu X, Wang H, Shi S, and Xiao J. Association between IL-6 and severe disease and mortality in COVID-19 disease: a systematic review and meta-analysis. *Postgrad Me J.* 2021. 0: 1–9
218. Sabaka P, Koscalova A, Straka I, Hodosy J, Liptak R, Kmotorkova B, *et al.* Role of interleukin-6 as a predictive factor for severe course of COVID-19: retrospective data analysis of patients from a long-term care facility during COVID-19 outbreaks. *BMC.* 2021. 21(318): 1–8
219. Pal K, Molnar AA, Hutanu A, Szederjesi J, Branea I, Timar A, *et al.* Inflammatory biomarker associated with in-hospital mortality in critical COVID-19 patients. *Int J Mol Sci.* 2022. 23: 1–12
220. Ahmed S, Jafri L, Hoodbhory Z, and Siddiqui I. Prognostic value of serum procalcitonin in COVID-19 patient: A systematic review. *Indian J Crit Care Med.* 2021. 25(1): 77–85
221. Aon M, Alsaeedi A, Alzafiri A, Ibrahim MM, Al-Shammari A, Al-Shammari O, *et al.* The association between admission procalcitonin level and the severity of COVID-19 pneumonia: A retrospective cohort study. *Medicina.* 2022. 58: 1–12

222. Kumar A, Karn E, Tivedi K, Kumar P, Chauchan G, Kumari A, *et al.* Procalcitonin as a predictive marker in COVID-19: A systematic review and meta-analysis. *Plos One*. 2022. 17(9): 1–22
223. Jackson I, Jaradeh H, Aurit S, Aldamen A, Narechania S, Destache C, *et al.* Role of procalcitonin as a predictor of clinical outcomes in hospitalized patients with COVID-19. *Int J Infect Dis*. 2022. 119: 47–52
224. Zattera L, Veliziotis I, Cano AB, Ramos I, Larranaga L, Nunuez M, *et al.* Early procalcitonin to predict mortality in critically ill COVID-19 patient: a multicentric cohort study. *Minerva Anesthesiol*. 2022. 88(4): 259–71

